Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Harbour BioMed OK'd to Start China Trial of CTLA-4 Antibody for NSCLC

publication date: Feb 26, 2021

Harbour BioMed was approved to start a China trial of its next-gen anti-CTLA-4 antibody in patients with advanced NSCLC and other solid tumors. The CTLA-4 antibody will be administered in combination with a PD-1 antibody or the PD-1 together with chemotherapy. HBM says the candidate is a fully human anti-CTLA-4 monoclonal heavy chain only antibody generated by its proprietary Harbour Mice® platform. HBM is headquartered in Cambridge, MA, with drug discovery operations in Rotterdam and an R&D facility in Suzhou. More details....

Stock Symbol: (HKEX: 02142)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital